NASDAQ:KDNY

Chinook Therapeutics Stock Forecast, Price & News

$13.89
+0.29 (+2.13 %)
(As of 04/13/2021 01:20 PM ET)
Add
Compare
Today's Range
$13.66
Now: $13.89
$14.07
50-Day Range
$14.38
MA: $16.80
$19.11
52-Week Range
$10.50
Now: $13.89
$21.68
Volume1,921 shs
Average Volume118,286 shs
Market Capitalization$588.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.26
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Chinook Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KDNY
CUSIPN/A
CIKN/A
Phone510-848-4400
Employees43
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.26 million
Book Value$4.07 per share

Profitability

Net Income$-82,370,000.00
Net Margins-215.80%

Miscellaneous

Market Cap$588.62 million
Next Earnings Date5/3/2021 (Estimated)
OptionableOptionable

Headlines

Chinook Therapeutics (NASDAQ:KDNY) Trading Down 9%
March 31, 2021 |  americanbankingnews.com
Chinook Therapeutics (NASDAQ:KDNY) Sees Strong Trading Volume
March 30, 2021 |  americanbankingnews.com
Chinook Therapeutics (NASDAQ:KDNY) Stock Price Down 4.8%
March 25, 2021 |  americanbankingnews.com
Chinook Therapeutics (NASDAQ:KDNY) Sees Large Volume Increase
March 24, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

647th out of 2,016 stocks

Pharmaceutical Preparations Industry

308th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$13.89
+0.29 (+2.13 %)
(As of 04/13/2021 01:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KDNY News and Ratings via Email

Sign-up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chinook Therapeutics (NASDAQ:KDNY) Frequently Asked Questions

Is Chinook Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Chinook Therapeutics stock.
View analyst ratings for Chinook Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Chinook Therapeutics?

Wall Street analysts have given Chinook Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chinook Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chinook Therapeutics' next earnings date?

Chinook Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Chinook Therapeutics
.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its earnings results on Tuesday, April, 6th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.82. Chinook Therapeutics had a negative net margin of 215.80% and a negative trailing twelve-month return on equity of 112.72%.
View Chinook Therapeutics' earnings history
.

What price target have analysts set for KDNY?

8 analysts have issued 12-month target prices for Chinook Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they anticipate Chinook Therapeutics' share price to reach $30.33 in the next twelve months. This suggests a possible upside of 118.1% from the stock's current price.
View analysts' price targets for Chinook Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Chinook Therapeutics' key executives?

Chinook Therapeutics' management team includes the following people:
  • Mr. Eric L. Dobmeier, Pres, CEO & Director (Age 52)
  • Mr. Ali Haddarah, Group Chief Financial Officer
  • Ms. Noopur Batsha Liffick, VP of Investor Relations & Corp. Communications
  • Mr. Kirk D. Schumacher J.D., Sr. VP & Gen. Counsel
  • Ms. Jodi Jamieson, VP of HR
  • Mr. Tom Frohlich, Chief Bus. Officer
  • Mr. Alan Glicklich M.D., Chief Medical Officer
  • Mr. Andrew James King D.V.M., Ph.D., Head of Renal Discovery & Translational Medicine
  • Ms. Renata Oballa Ph.D., VP of Research Operations & Vancouver Site Head

Who are some of Chinook Therapeutics' key competitors?

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

How do I buy shares of Chinook Therapeutics?

Shares of KDNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $13.91.

How much money does Chinook Therapeutics make?

Chinook Therapeutics has a market capitalization of $589.46 million and generates $17.26 million in revenue each year. The company earns $-82,370,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

Chinook Therapeutics employs 43 workers across the globe.

What is Chinook Therapeutics' official website?

The official website for Chinook Therapeutics is chinooktx.com.

Where are Chinook Therapeutics' headquarters?

Chinook Therapeutics is headquartered at 740 HEINZ AVENUE, BERKELEY CA, 94710.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The company can be reached via phone at 510-848-4400 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.